HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

acrizanib

VEGFR-2 inhibitor for topical treatment of age-related macular degeneration

Also Known As:

LHA510; N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - acrizanib: 2
  - Pyrimidines: 510
    - acrizanib: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - acrizanib: 2

Experts

1.	Adams, Christopher M: 2 articles (01/2022 - 01/2018)
2.	Bhatt, Harit: 1 article (01/2022)
3.	Browning, David J: 1 article (01/2022)
4.	Chastain, James: 1 article (01/2022)
5.	Ciulla, Thomas A: 1 article (01/2022)
6.	Ferriere, Michael: 1 article (01/2022)
7.	Gedif, Kinfemichael: 1 article (01/2022)
8.	Glazer, Louis C: 1 article (01/2022)
9.	Grosskreutz, Cynthia L: 1 article (01/2022)
10.	Joondeph, Brian C: 1 article (01/2022)

Related Diseases

1.

Macular Degeneration (Age-Related Maculopathy)

01/01/2018 - "The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration."
01/01/2022 - "A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration."
01/01/2022 - "To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age-related macular degeneration. "

Related Drugs and Biologics

1.	acrizanib
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
4.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
5.	Protein-Tyrosine Kinases (Tyrosine Kinase)

Related Therapies and Procedures

1.	Therapeutics